

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-18 (canceled)

19. (New). A method of treating a patient suffering from a proliferative disease comprising administering an effective amount of a bisphosphonate wherein the bisphosphonate acts to reduce angiogenesis and is selected from the following compounds 3-amino-1-hydroxypropane-1,1-diphosphonic acid; 3-(N,N-dimethylamino)-1-hydroxypropane-1,1-diphosphonic acid; 1-hydroxy-ethidene-bisphosphonic acid; 1-hydroxy-3-(methylpentylamino)-propylidene-bisphosphonic acid; 6-amino-1-hydroxyhexane-1,1-diphosphonic acid; 3-(N-methyl-N-n-pentylamino)-1-hydroxypropane-1,1-diphosphonic acid; 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid; 1-hydroxy-2-(3-pyridyl)ethane-1,1-diphosphonic acid (risedronic acid); 1-(4-chlorophenylthio)methane-1,1-diphosphonic acid (tiludronic acid); 1-hydroxy-3-(pyrrolidin-1-yl)propane-1,1-diphosphonic acid; 1-(N-phenylaminothiocarbonyl)methane-1,1-diphosphonic acid; 5-benzoyl-3,4-dihydro-2H-pyrazole-3,3-diphosphonic acid tetraethyl ester; 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diphosphonic acid; and 1,1-dichloromethane-1,1-diphosphonic acid and wherein the proliferative disease is selected from rheumatoid arthritis, osteoarthritis, breast cancer, colon cancer, small cell lung cancer, prostate cancer, diabetic retinopathy, psoriasis, haemangioblastoma and haemangioma.

20. (New). The method according to claim 19, in which the bisphosphonate is used for the embolic treatment of angiogenesis.

21. (New). The method according to claim 19, in which the bisphosphonate is selected from pamidronic acid, or a pharmaceutically acceptable salt thereof, or any hydrate thereof.

22. (New). The method according to claim 19, in which the bisphosphonate is selected from zoledronic acid, or a pharmaceutically acceptable salt thereof, or any hydrate thereof.